- Quick overview of 340B program and why it's experienced such strong growth
- How does the program help/hurt health systems & biopharma companies (I understand that some biopharmas offer 340B discounts that surpass the mandated % in order to gain market share.)
- What's the likelihood of 340B reform passing and, if it does, what would reform likely look like?
- How has the Trump administration changed the calculus on the likelihood of reform?
- How would reforms affect stakeholders such as health systems, biopharma companies, drug distributors, PBMs ?
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Opinion: Discussing the current state of the 340b program and how potential reforms would affect health systems.
Ticker(s): CVS, ABBV, SNY, LLY, NVS, NVO, WMTWho's the expert?
Insittution: Self Employed
- Healthcare consultant with over 20 years of experience.
- Comfortable speaking to the current state of the 340b drug pricing program plus possibilities for the future
Interview Goal
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
